GLP-1 Affiliate Programs for Approved Publishers

The opportunity

GLP-1 medications changed how people search for weight help. Instead of diet products, a large share of high-intent searches now look for a clinician who can evaluate them and, if appropriate, prescribe. Telehealth programs fill that gap with online intake, clinician review, prescriptions sent to a pharmacy, and ongoing check-ins.

For publishers, that creates three things worth having: high search demand, a long research phase where trusted content wins, and subscription programs where a patient may stay for months. It also creates risk. GLP-1 marketing has drawn more regulatory attention than almost any other telehealth category, so the publishers who last are the ones who get the rules right.

How GLP-1 telehealth programs work

Most programs follow the same path: an online health intake, review by a licensed clinician, a prescription if the clinician decides it's appropriate, and medication shipped from a pharmacy. Ongoing membership usually covers follow-ups, dose adjustments and support. Programs differ in what's included, how pricing works and which medications they offer.

Commission structures in this category usually follow the conversion event: CPA on the first paid month or fill, CPL on completed intakes for programs with a care team, and revenue share or hybrid models for programs with strong retention. Exact terms are shared with approved publishers.

Best-fit traffic

GLP-1 programs reward publishers who own trust and intent. The strongest sources are the ones where a reader is already researching:

• SEO content and comparison sites: cost guides, program comparisons and "how it works" explainers. Comparison sites must disclose that they're paid, and can't present themselves as independent if they aren't.
• Email newsletters: health and wellness lists with opt-in consent, especially with a sequence that explains how telehealth weight care works.
• YouTube and podcasts: long-form explainers and honest program walkthroughs with on-screen and spoken disclosure.
• Creators: allowed with approved scripts. Personal experience must be real, typical results must be clear, and disclosure must be upfront.

Paid search and paid social are approval-required. Google requires telemedicine advertisers in the US to hold LegitScript certification plus Google's own healthcare certification, and that certification belongs to the provider. Expect most GLP-1 briefs to restrict or prohibit affiliate paid search on prescription and brand terms.

See telehealth ad platform rules for what each platform requires.

Category rules

On March 3, 2026, FDA sent 30 warning letters to telehealth companies over their marketing of compounded GLP-1 medications. FDA objected to marketing that implied compounded drugs were the same as FDA-approved products or equivalent to generics, and to own-brand names that hid who actually compounded the drug. It followed an earlier wave of drug-advertising enforcement in September 2025. In December 2025 the FTC finalized an order against NextMed, a GLP-1 telehealth company, over misleading prices, fake reviews and deceptive weight-loss claims.

Compounding rules are also still moving. On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, which would stop outsourcing facilities from compounding them from bulk ingredients. A final decision is pending; see the regulation tracker for the latest.

Those actions targeted the companies, but publisher content that repeats the same claims spreads the same risk. These rules apply to every GLP-1 offer on MarketHealth, on top of each offer's brief:

The full list, with examples, is in the GLP-1 section of the compliance guide.

How to evaluate a GLP-1 program before you promote it

Your readers will judge you by the programs you recommend. Before you accept any GLP-1 offer, on MarketHealth or anywhere else, check these points. We check them too before an advertiser is listed.

• Clinical process: is there a real clinician review, and can a clinician say no? Programs that "approve" almost everyone are a red flag.
• Pharmacy transparency: does the program say which pharmacy fills the prescription, and whether the medication is branded or compounded?
• Pricing clarity: are the membership fee, medication cost and renewal terms all shown before checkout?
• Cancellation: can a patient cancel online, as easily as they signed up? The FTC's 2026 action against a large telehealth brand included hard-to-cancel subscriptions.
• Certification: does the advertiser hold LegitScript certification, and which states are its clinicians licensed in?
• Ongoing care: are follow-ups, dose adjustments and side-effect questions handled by clinicians, not just a chatbot?

A program that passes all six converts better over time, because patients stay and refund less. That's what makes revenue-share and recurring commissions worth having.

Content that works and stays compliant

The best-performing GLP-1 content answers the questions patients actually ask, without promising outcomes:

1. Cost explainers: what's included in a program membership, what's billed separately, and how insurance or savings programs fit in.
2. How-it-works guides: intake, clinician review, prescription, shipping and follow-up, step by step.
3. Program comparisons: clinician access, labs, coaching, pricing transparency and cancellation terms, with your paid relationships disclosed.
4. Branded vs compounded explained: a neutral explanation of the difference, written with the advertiser's approved language.
5. Eligibility questions: who programs typically evaluate, framed as "a clinician will decide", never as a self-qualification promise.
6. Life on a program: follow-ups, side-effect questions to raise with a clinician, and nutrition support, without medical advice.